Allogenic umbilical cord tissue for temporomandibular joint injuries

Frontiers in Pain Research

Pain Research

Nicola Maffulli¹  Samir Ghandour²  Manu Gupta³  Ashim Gupta⁴  Adarsh Aratikatla⁵ 

[1] Department of Musculoskeletal Disorders, School of Medicine and Surgery, University of Salerno, Fisciano, Italy;San Giovanni di Dio e Ruggi D’Aragona Hospital “Clinica Orthopedica” Department, Hospital of Salerno, Salerno, Italy;Barts and The London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, Queen Mary University of London, London, United Kingdom;School of Pharmacy and Bioengineering, Keele University School of Medicine, Stoke on Trent, United Kingdom;Faculty of Medicine, The University of Balamand, Beirut, Lebanon;Polar Aesthetics Dental & Cosmetic Centre, Noida, India;Regenerative Orthopaedics, Noida, India;Future Biologics, Lawrenceville, GA, United States;BioIntegrate, Lawrenceville, GA, United States;South Texas Orthopaedic Research Institute (STORI Inc.), Laredo, TX, United States;The Royal College of Surgeons in Ireland, Dublin, Ireland;

关键词: umbilical cord;    Wharton’s jelly;    mesenchymal stem cells;    regenerative medicine;    temporomandibular joint;    TMJ;   

DOI  :  10.3389/fpain.2023.1281277

 received in 2023-08-22, accepted in 2023-10-16,  发布年份 2023

来源: Frontiers

【 摘 要 】

The temporomandibular joint (TMJ) is crucial for functions of daily living such as mastication and articulation. Common TMJ issues include osteoarthritis, internal derangement, and myofascial pain dysfunction. Conservative methods such as physical therapy and medications are used, with surgical options such as arthroscopy and replacement for severe cases. Emerging regenerative medicine explores non-surgical treatments using human stem cells from umbilical cord derivatives, showing potential for tissue regeneration in TMJ disorders. A systematic search was conducted across PubMed, Embase, Scopus, and Web of Science databases, adhering to PRISMA guidelines, aiming to identify relevant articles published in English until August 2023. The search used specific terms to target in vitro, preclinical, and clinical studies on umbilical cord (UC)-derived tissue and mesenchymal stem cells (MSCs) for treating TMJ disorders. The search was extended to three clinical trial registries for on-going investigations related to UC tissue and MSCs for TMJ disorder management. The studies included in this article report the safety and efficacy profiles of allogenically acquired, umbilical cord-derived tissues and associated mesenchymal stem cells for temporomandibular joint ailments, future adequately powered, randomized controlled trials are warranted to conclusively justify the clinical use of this biologic therapy.

【 授权许可】

Unknown   
© 2023 Aratikatla, Ghandour, Maffulli, Gupta and Gupta.